Drug-related side effects and adverse reactions in the treatment of migraine: a bibliometric and visual analysis

Background Migraine imposes a substantial global burden, impacting patients and society. Pharmacotherapy, as a primary treatment, entails specific adverse reactions. Emphasizing these reactions is pivotal for improving treatment strategies and enhancing patients’ well-being. Thus, we conducted a comprehensive bibliometric and visual analysis of relevant literature. Methodology We conducted a comprehensive search on the Science Citation Index Expanded within the Web of Science, restricting the literature for analysis based on criteria such as document type, publication date, and language. Subsequently, we utilized various analytical tools, including VOSviewer, Scimago Graphica, the R package ‘bibliometrix’, CiteSpace, and Excel programs, for a meticulous examination and systematic organization of data concerning journals, authors, countries/regions, institutions, keywords, and references. Results By August 31, 2023, the literature was distributed across 379 journals worldwide, authored by 4,235 individuals from 1726 institutions. It featured 2,363 keywords and 38,412 references. ‘HEADACHE’ led in publication count, with ‘SILBERSTEIN S’ as the most prolific author. The United States ranked highest in publication volume, with ‘UNIV COPENHAGEN’ leading among institutions. Conclusion Our research findings indicate that researchers in the field continue to maintain a focus on the calcitonin gene-related peptide (CGRP) system and explore diverse mechanisms for drug development through the application of novel biotechnological approaches. Furthermore, it is imperative to enhance the assessment of clinical trial outcomes, consistently monitor the efficacy and safety of prominent drugs such as Erenumab and Fremanezumab. There is a need for further evaluation of acute and preventive treatments tailored to different populations and varying types of migraine.


Introduction
Migraine, a highly prevalent neurological disorder, affects over 15% of the global population and stands as the second leading cause of disability (1).Migraine imposes a  (2).Clinically, it is characterized by recurrent, pulsating, unilateral, moderate-to-severe headaches lasting 4 to 72 h, often accompanied by symptoms such as nausea, vomiting, photophobia, and phonophobia (3).The intricate pathophysiological mechanisms of migraine involve the significant involvement of the trigeminovascular system, gaining widespread attention (4).Additionally, various factors, including hormonal influences (5) and genetic predispositions (6), are believed to play a crucial role in the progression of migraine.Presently, drug therapy remains the cornerstone of migraine treatment, encompassing opioids, triptans, CGRP receptor antagonists, antidepressants, antiepileptic drugs, nonsteroidal anti-inflammatory drugs, among others (7).Among these, preventive medications encompass tricyclic antidepressants, antiepileptics, beta-blockers, and others.In the category of acute (abortive) drugs, triptans and nonsteroidal anti-inflammatory drugs are typically favored as first-line options, while opioids are generally considered a last resort (8).However, the use of these medications may also result in adverse effects, and certain side effects may occasionally persist even after discontinuation of preventive therapy (9).While some side effects may manifest as mild drowsiness or nausea, others can lead to severe complications compromising patient well-being.Therefore, conducting clinical research on drugrelated adverse reactions, refining adverse reaction reporting standards in clinical treatment and research, and gaining a comprehensive understanding of the severity and nature of adverse effects hold significant clinical importance.
Over the past few decades, research pertaining to Drug-Related Side Effects and Adverse Reactions in the treatment of migraine has witnessed continual development.A comprehensive understanding of the overall landscape and research trends in this field is of paramount significance.Bibliometrics, as a method for the holistic analysis of publications within a specific domain, plays a pivotal role in enabling researchers to grasp an overview of research within the field (10)(11)(12).However, we have not identified any bibliometric studies specifically focusing on Drug-Related Side Effects and Adverse Reactions in migraine treatment.Consequently, these medication-related adverse effects merit our earnest attention.
Therefore, we conducted a thorough assessment of relevant literature within the field through bibliometric analysis and visualization.This involved synthesizing information related to publications, journals, authors, countries, institutions, keywords, and cited references.In doing so, we have delineated the developmental trajectory of pertinent research and speculated on future research directions.We firmly believe that this study will facilitate researchers in comprehending the evolution of the research domain, and aid scholars in embarking on new investigations to make novel discoveries.

Data collection
On September 20, 2023, we conducted a literature search in The Web of Science (WOS) Science Citation Index Expanded (SCI-Expanded) database. 1The search formula used was as follows: (

Data analysis and visualization
Two researchers independently reviewed the included literature, manually correcting spelling errors and consolidating overlapping items into singular elements.In cases of disagreement, a third researcher was consulted to reach a consensus.
This study utilized VOSviewer (version 1.6.19)(13), Scimago Graphica (version 1.0.35)(14), the R package "bibliometrix" (version 4.3.1)2(15), CiteSpace (version 6.2.R4) (16), and Microsoft Office Excel 2021 for bibliometric analysis and visualization.VOSviewer and Scimago Graphica were employed for co-authorship and co-occurrence analysis.CiteSpace was utilized for reference and keyword analysis.The R package "bibliometrix" was used for calculating relevant bibliometric indicators such as the number of publications (NP), the number of citations (NC), h-index, g-index, and for visualizing the yearly publication output of journals/authors, along with historiographic analysis.Microsoft Office Excel 2021 was utilized for the comprehensive compilation of the relevant data.

General analysis of publication status
According to the retrieval strategy (Figure 1), a total of 1,312 publications were identified as of August 31, 2023.After excluding other types of articles, 1,279 articles and reviews remained.Following the exclusion of non-English publications, 1,201 items were included in the study.These publications span 60 countries/regions, 379 journals, involve 4,235 authors, and are affiliated with 1726 institutions.

Times cited and publications over time
We depict the distribution of Times Cited and Publications in Figure 2. The Times Cited exhibits a discernible growth trend, reaching its peak at 3841 citations in 2021.The number of publications per year demonstrates that, from 1999 to 2018, the majority of the years maintained a publication count ranging between 30 and 40, with 2012, 2013, and 2015 exceeding 50 publications.The years 2019 to 2021 show a marked upward trajectory, with the number of publications reaching its maximum at 96 in 2021.Subsequently, both Times Cited and Publications have been sustained at a significantly elevated level.

Article analysis
Collectively, these publications have garnered 40,165 citations, with an average of 33.44 citations per article and an h-index of 86.Notably, eight publications have received over 400 citations each.
Topping the list, "Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine" has been cited the most, accumulating a total of 989 citations.This article substantiates the significant therapeutic efficacy and safety of the CGRP Receptor Antagonist BIBN 4096 BS in the acute treatment of migraines through an international, multicenter, double-blind randomized clinical trial (17).Following closely is the publication titled "Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials, " with a cumulative citation count of 728.The authors analyzed 53 clinical trials involving 24,089 patients to observe the efficacy and good tolerability of oral triptans as selective serotonin 5-HT(1B/1D) agonists in the treatment of acute migraines (18).Furthermore, the publication titled "Topiramate for migraine prevention: a randomized controlled trial" has garnered a total of 533 citations.Through a 26-week, randomized, double-blind, placebocontrolled study across 52 North American clinical centers, the authors concluded that topiramate demonstrates significant preventive effects against migraines but may result in side effects such as paresthesia, fatigue, and nausea (19).Collectively, these highly cited publications have accrued over 2,100 citations, each exceeding 500 citations.

Journal analysis
Cluster analysis is a method for grouping highly similar targets (20).The h-index, a commonly used bibliometric indicator, is positively correlated with the quantity of publications and total citations (21).In comparison, the g-index offers a more precise evaluation of the contribution of highly cited items (22).Journal Impact Factor (JIF) and JIF Quartile data are obtained from the 2022 Journal Citation Reports. 3 This study encompassed an analysis of 379 journals.By setting the 'Minimum number of documents of a source' to 3 in VOSviewer, we selected 93 qualifying journals.Subsequently, a visual analysis was conducted using VOSviewer and Scimago Graphica, as illustrated in Figure 3.The analyzed journals were primarily divided into 14 clusters.Table 1 presents

Author analysis
This study involves an extensive analysis of 4,235 authors.We consolidated similar author names, such as Silberstein, SD and Silberstein, S, and by setting the 'Minimum number of documents of an article' to 4 in VOSviewer, we ultimately identified 142 eligible CiteSpace-based dual map overlay of journals.authors.Subsequently, we conducted a visual analysis using VOSviewer and Scimago Graphica, as depicted in Figure 5.The analyzed journals were primarily categorized into 13 clusters.Table 2 presents the top 10 authors based on NP.The author with the highest NP is Silberstein, S (N = 37), followed by

Country/region and institution analysis
This study encompasses 60 countries/regions.To ensure the reliability of our findings, we amalgamated certain country names, such as combining England, North Ireland, Scotland, and Wales into the United Kingdom.Subsequently, employing VOSviewer and Scimago Graphica, we visually analyzed 47 key countries, divided into 11 clusters, selected using VOSviewer with the setting 'Minimum number of documents of a country = 2' (Figure 6).The United States has established the most extensive national collaborative network, with a total link strength of 227, spanning 32 countries/regions.Table 3 displays the top 10 countries/regions based on NP ranking.The country with the highest NP is the United States (N = 481), followed by Italy (N = 163) and the United Kingdom (N = 117).The USA (N = 20,967) also leads in NC, followed by the United Kingdom (N = 8,353) and Germany (N = 5,266).The United Kingdom boasts the highest average citations (N = 71.39),followed by the Netherlands (N = 59.68) and Germany (N = 58.51).
Subsequently, we applied a 'Minimum number of documents of an organization = 5' setting to filter 103 institutions from a total of 1726, categorizing them into 12 clusters (Figure 7).Table 3 illustrates the top 10 institutions based on NP ranking.The institution with the highest NP is Univ Copenhagen (N = 55), followed by Albert Einstein Coll Med (N = 28) and Mayo Clinic (N = 25).The institution leading in NC is Albert Einstein Coll Med (N = 2,858), followed by Univ Copenhagen (N = 2,586) and Leiden Univ (N = 2,167).Leiden Univ boasts the highest average citations (N = 103.19), followed closely by Albert Einstein Coll Med (N = 102.07)and Mayo Clinic (N = 76.84).Albert Einstein Coll Med (N = 57) and Univ Copenhagen (N = 33) demonstrate the highest Total Link Strength and Links, respectively.Notably, Univ Oxford exhibits the lowest Total Link Strength (N = 2) and Links (N = 2) among the top 10 institutions.

Research direction
In the field, the literature can be categorized into various research directions based on Web of Science Categories.The most prominently observed categories are Clinical Neurology Network visualization of Authors that contributed to the papers (A: Total number of publications and citations; B: Total link strength and cluster; C: Authors' production over time; D: Publication changes year by year.The larger the graph area, the more the number of individual units, and the thicker the lines between the two units, the stronger the correlation).

Keyword analysis
Citespace has been utilized for keyword co-occurrence and clustering analysis.Co-occurrence analysis is a method that examines the frequency and patterns of the simultaneous occurrence of different research subjects (24).Burstiness describes a phenomenon where the frequency of appearance of a particular research subject significantly increases within a specific time frame (25).Among all 2,363 keywords, we merged those with similar meanings, such as 'cgrp' and 'calcitonin gene-related peptide' , 'prevention' and 'preventive treatment' , and others.Subsequently, using a scale factor k = 9 in Citespace, we finally filtered 277 keywords for analysis.The obtained data are evaluated as shown in Figure 8 and Table 4.   ).Subsequently, we conducted cluster analysis and visualization using the log-likelihood ratio algorithm.As the cluster map (Q = 0.4116, S = 0.7319) indicated Q > 0.3 and S > 0.5, the clustering quality was deemed satisfactory (12).These keywords were mainly divided into 10 clusters: Cluster #0 'topiramate' , Cluster #1 'efficacy' , Cluster #2 'CGRP' , Cluster #3 'etiology' , Cluster #4 'central nervous system' , Cluster #5 'valproic acid' , Cluster #6 'dichotomous outcome measures' , Cluster #7 'cluster headache' , Cluster #8 'acute treatment' , and Cluster #9 'menstrually related migraine' .

Reference analysis
Citespace was employed for keyword co-occurrence and clustering analysis.Utilizing a scale factor k = 3 in Citespace, a meticulous screening process was conducted among 38,087 referenced articles, resulting in 265 articles that were included for analysis and subsequent visualization.The data obtained were evaluated as demonstrated in Figure 9 and Table 5. Notably, the most frequently cited references were the 'Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition' (N = 67), followed by ' A Controlled Trial of Erenumab for Episodic Migraine' (N = 56), and 'Migraine Pathophysiology and Its Clinical Implications' (N = 45).The log-likelihood ratio algorithm was employed for the clustering analysis, revealing 12 principal clusters in the field, as indicated in the cluster map (Q = 0.8105, S = 0.9414): Cluster #0 Monoclonal Antibody,

General information
This study represents the inaugural application of bibliometric analysis to investigate the developmental status and trends within the fields of Migraine and Drug-Related Side Effects and Adverse Reactions in the Web of Science Core Collection (WOSCC) from January 1, 1998, to August 31, 2023.Encompassing a corpus of 1,201 Network visualization of the Institutions that contributed to the papers (A: Total number of publications and citations; B: Total link strength and cluster; C: Publication changes year by year.The larger the graph area, the more the number of individual units, and the thicker the lines between the two units, the stronger the correlation).Based on the annual trends observed in the published literature and citations, a significant upsurge in citations is apparent, indicating a notable surge in the field's attention since 1999.For the majority of the period between 1999 and 2018, the quantity of publications ranged between 30 and 40 articles, with notable peaks in 2012, 2013, and 2015, surpassing 50 articles.Notably, the years 2019 to 2021 exhibited a remarkable growth trajectory, sustaining a high level thereafter.As of our latest literature review, up until August 31, 2023, the field's prominence continues to remain elevated, as indicated by the combined tally of 2,479 citations and 45 publications in the initial 8 months of the year (Figure 2).
In the realm of journal analysis, the prominent positions held by HEADACHE and CEPHALALGIA, ranking first and second in terms of NP, NC, total link strength, h-index, and g-index, alongside their commendable performance in other pertinent indicators, solidify their standing as the most influential journals in the field.Notably, NEUROLOGY and COCHRANE DATABASE OF SYSTEMATIC REVIEWS boast the highest average citations and JIF, underscoring the high caliber and widespread recognition of their publications.The annual publication trends of these journals underscore the recent dominance of HEADACHE and CEPHALALGIA in the field, while also highlighting the positive trajectory of the JOURNAL OF HEADACHE AND PAIN in recent years.Furthermore, the evolutionary relationships in journal publication over time suggest that journals like Frontiers in Neurology and Expert Opinion on Drug Safety might be emerging as novel forces in this domain (Figure 3; Table 1).The dual journal map delineates the intricate interrelations between citing and cited literature, indicating the multidisciplinary, multi-themed, and cross-disciplinary nature of the related research in this domain, necessitating researchers to possess a broad perspective and diverse knowledge base (Figure 4).
Concerning author analysis, taking all included metrics into account, it is apparent that SILBERSTEIN S and GOADSBY PJ wield significant influence in the field.Despite a lower NP count (N = 19), DIENER H secures the second-highest average citations (133.84),indicating widespread acclaim for the quality of his publications.LIPTON RB's highest total link strength signifies a closely collaborative relationship with other researchers within the field.The annual publication trends of authors reveal the sustained impact exerted by SILBERSTEIN S, GOADSBY PJ, LIPTON RB, and MAASSENVANDENBRINK A. Similarly, the evolutionary relationships in journal publication over time suggest that individuals such as TASSORELLI C and WANG X might be promising authors worthy of attention within the field (Figure 5; Table 2).
Analyses of the countries/regions reveal that the major impactdriving forces in this field are primarily concentrated in North America and Europe, where intricate and extensive networks of collaboration have been established.The collaborative network established by the United States encompasses the highest number of countries/regions, thus yielding the highest NP, NC, Total Link Strength, and Links, making it the most influential country in this field.The United Kingdom boasts the highest Average Citations and   7; Table 3).

Knowledge base and future perspectives
The most prevalent keywords underscore the meticulous demands of clinical research methods in this field, emphasizing the epidemiology and burden of migraine, with a focus on drug therapies and their characteristics.The assessment encompasses treatment efficacy, safety, and tolerability, while maintaining a keen interest in pain management and mechanistic research.The clustering of keywords highlights diverse research directions, including etiology, mechanisms, crucial targets, multiple drug approaches, efficacy evaluations, and various types of migraine.The keyword clustering underscores distinct research domains such as etiology, the pivotal role of calcitonin-gene related peptide as a key factor in this condition, and several drugs, including topiramate and valproic acid.Researchers have concentrated their attention on the central nervous system's organizational structure, emphasizing the application of dichotomous outcome measures to enhance the reliability of efficacy assessments.Moreover, acute treatment and different types of migraines, such as cluster headaches and menstrually related migraines, have garnered significant attention within this field.Around 1999-2010, researchers primarily focused on the prevention, treatment efficacy, and safety of migraine, emphasizing the crucial role of the double-blind placebo in experimental design.Meanwhile, there was a gradual increase in the application of sumatriptan for migraine management, with growing attention on calcitonin gene-related peptide as a significant factor in migraine.Around 2010-2015, researchers gradually amplified their focus on episodic migraine, exhibiting strong interest in CGRP receptors, CGRP receptor antagonists, and monoclonal antibodies.The American Academy and Quality Standards Subcommittee emerged as the most influential academic entities in this field.Around 2015-2020, there was a gradual increase in reports related to three drugs targeting the CGRP system, namely erenumab, amg 334, and ubrogepant.The emergency department became a new focal point, and the critical role of the blood-brain barrier received further affirmation.As of 2023, there has been a significant emphasis on the role of questionnaires in evaluations.New research focuses on 5-ht1f receptor agonists, apoptosis, amylin, and antidepressants, among others.Burstiness analysis of the keywords demonstrates that researchers are particularly focused on trial methods, experimental design, efficacy assessment, and various types of drugs.Based on the current persistently impactful keywords, we predict that future research in this field may concentrate on episodic migraine, calcitonin gene-related peptide, and related drugs, aiming to find robust evidence through clinical trials (Figure 8; Table 4).The most cited literature highlights researchers' emphasis on the precise diagnosis of migraine types (3, 26), exploring the pathophysiological mechanisms of this condition, and the consequent development of various pharmacological treatments (27)(28)(29).Meningitis has garnered attention from researchers in the field (30).A meta-analysis involving 24,089 patients and 53 clinical trials demonstrated the effectiveness and good tolerability of all oral triptan class drugs (18).Five studies investigated the CGRP system-related drugs Erenumab and Fremanezumab.A 12-week study involving 1,130 patients revealed that compared to a placebo, Fremanezumab significantly reduced the frequency of headaches, with main adverse reactions being injection-site reactions primarily characterized by pain (31).Four studies confirmed the preventive and therapeutic effects of Erenumab on episodic and chronic migraines, as well as its potential as an ideal option for patients with difficult-to-treat migraines.The safety profile of Erenumab was found to be similar to the placebo across the four studies, with the most common adverse events being injection site pain, upper respiratory tract infections, nausea, and nasopharyngitis (32)(33)(34)(35).Cluster analysis encompassed various aspects of the research, including etiology, the calcitoningene-related peptide as a key factor in migraines, the widely discussed monoclonal antibodies, and multiple drugs such as eletriptan, telcagepant, non-steroidal anti-inflammatory drugs, and topiramate.Transcranial magnetic stimulation, as a non-invasive and relatively safe therapy, has gained widespread application.Additionally, acute treatments and the special group of children have received special attention from researchers in the field.Burstiness analysis of references indicates that the precise diagnosis and pathophysiology of migraines, the role of meningitis, and the future potential of the drugs Erenumab and Fremanezumab are likely to continue to be of enduring interest among researchers in the field (Figure 9; Table 5).
In-depth understanding of the developmental trajectory in this field can be attained through a comprehensive analysis and interpretation of seminal literature, key terms, and results from reference bibliographies.Leveraging the historiographic analysis feature within the R package 'bibliometrix, ' we identified a set of 15 seminal publications within this domain.Subsequently, we generated visualizations, annotating key insights extracted from these publications (Figure 10).By amalgamating the primary findings from these 15 publications, it becomes evident that the majority of research endeavors have been devoted to conducting high-quality clinical trials investigating the efficacy and safety of various pharmaceutical agents.These therapeutic agents encompass a diverse range, each exploiting distinct mechanisms of action.Notably, these include a multitude of triptan-class drugs such as Eletriptan and Sumatriptan, acting as SEROTONIN 5-HT1B/1D AGONISTS (36).Additionally, there are SELECTIVE SEROTONIN 1F (5-HT1F) RECEPTOR AGONIST

Neurology
The Lancet.
According to our analysis, drugs targeting the calcitonin generelated peptide (CGRP) system undeniably represent a focal point in current migraine therapeutics.Two categories of drugs address the CGRP system: monoclonal anti-CGRP antibodies, including Erenumab, Fremanezumab, Galcanezumab, and Eptinezumab; and CGRP receptor antagonists, including Ubrogepant, Rimegepant, Atogepant, and Zavegepant.These drugs have demonstrated commendable clinical efficacy, and their safety profiles have been endorsed, with predominantly mild to moderate side effects.However, some studies have reported data inconsistent with clinical trials.For example, Erenumab may have a higher likelihood of causing constipation in patients and a higher discontinuation rate (71).Erenumab treatment appears to be significantly associated with hypertension (72).Furthermore, case reports have described drugrelated myocardial infarction (73)  potentially have higher efficacy and similar tolerability (75).Additionally, various CGRP-targeting drugs are thought to increase the risk of alopecia (76).As these drugs have been approved for marketing only in recent years [especially Zavegepant, which was approved this year (77)], there is currently a lack of comprehensive reporting on drug-related side effects.The long-term effectiveness and safety of these drugs require further investigation.In the future, more detailed and reliable evidence for drug assessment can be facilitated through the implementation of long-term, crossregional, multicenter, large-scale randomized controlled trials and real-world studies.

Limitations
Several limitations are present in this study.Firstly, only data from the WOS-SCIE database were included, ensuring the quality of evidence but possibly overlooking some relevant studies.To minimize subjective inclusion differences, we refrained from conducting further manual screening of the included literature, enhancing the objectivity of the analysis but potentially compromising the precision of the study.Non-English publications were excluded, potentially underestimating the impact of non-English scholarly contributions.Additionally, due to data constraints, publications beyond September 2023 were not incorporated.

Conclusion
In summary, our study synthesizes the knowledge base in the field of migraine and Drug-Related Side Effects and Adverse Reactions, while also forecasting the developmental trends in this domain.We conducted visual analyses of pivotal journals, authors, countries/regions, institutions, keywords, and references contributing to this field.Our findings suggest that researchers are likely to sustain their focus on the CGRP system and conduct research on 5-ht1f receptor agonists, apoptosis, amylin, and antidepressants, alongside the development of novel drugs based on monoclonal antibody technology.Continuous attention to the efficacy and safety of various prominent drugs, such as renumab and Fremanezumab, is crucial, given the wealth of new evidence continually provided by large-scale randomized controlled clinical trials.Further, it is imperative to conduct larger-scale evaluations of acute and preventive treatments for different populations and migraine types.Exploration into the precise diagnosis of migraine and its pathophysiological mechanisms, with a focus on central nervous system and meningeal tissue structures, is also recommended.To ensure high-quality evidence, we propose enhancing the application of dichotomous outcome measures and questionnaires in the assessment of clinical trial results.
7 Recommendations for healthcare professionals 1 Conduct large-scale, multi-center, double-blind, placebocontrolled, and randomized clinical trials targeting diverse regions, ethnicities, ages, and genders. 2 Assess the safety of medications during specific physiological phases such as the perimenstrual period, pregnancy, and menopause.
the top 10 journals based on NP.Sixty percent of the top 10 journals are positioned in Quartile 1 of the Journal Citation Reports.The journal with the highest NP is HEADACHE (N = 152), followed by CEPHALALGIA (N = 94).Similarly, for the highest NC, HEADACHE (N = 6,266) and CEPHALALGIA (N = 4,035) lead the list.NEUROLOGY (N = 65.67)secures the highest position for Average Citations, followed by

FIGURE 2
FIGURE 2Year of publication and citation.

FIGURE 3
FIGURE 3Network visualization of the Journal that contributed to the papers (A: Total number of publications and citations; B: Total link strength and cluster; C: Journals' production over time; D: Publication changes year by year.The larger the graph area, the more the number of individual units, and the thicker the lines between the two units, the stronger the correlation).

FIGURE 6
FIGURE 6Networks showing the collaboration among Countries/regions in the papers (A: Total number of publications and clusters; B: Total link strength and citations; C: Publication changes year by year.The larger the graph area, the more the number of individual units, and the thicker the lines between the two units, the stronger the correlation).

FIGURE 8
FIGURE 8Network visualization of the Keyword clustering analysis of the papers changes by year and Keyword Burstiness (A: Keyword clustering analysis of the papers changes by year; B: Dynamically evolving high burstiness keywords change by year; C: Network visualization of the Keywords with the strongest citation bursts of the papers.The larger the graph area, the more the number of individual units, and the thicker the lines between the two units, the stronger the correlation).

FIGURE 9 TABLE 5
FIGURE 9Network visualization of the Co-cited references clustering analysis of the papers changes by year and Co-cited references Burstiness (A: Network visualization of the co-occurring references; B: Network visualization of the high burstiness references; C: cluster analysis of references; D: Network visualization of the references with the strongest citation bursts of the papers.The larger the graph area, the more the number of individual units, and the thicker the lines between the two units, the stronger the correlation).

TABLE 1
The top 10 most productive journals.

TABLE 2
The top 11 most productive journals.

TABLE 3
The top 10 most productive countries/regions and institutions.

TABLE 4
The top 10 keywords and clusters of keywords cooccurring in the papers.

TABLE 5 (
and ocular myasthenia gravis-like symptoms (74).Galcanezumab, on the other hand, is considered to Continued)